- Previous Close
0.00 - Open
0.64 - Bid --
- Ask --
- Day's Range
0.64 - 0.64 - 52 Week Range
0.64 - 6.40 - Volume
1,000 - Avg. Volume
4 - Market Cap (intraday)
27.529M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
www.kadimastem.comRecent News: KMSTF
View More
Performance Overview: KMSTF
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KMSTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KMSTF
View MoreValuation Measures
Market Cap
28.81M
Enterprise Value
35.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.45%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.55M
Diluted EPS (ttm)
-1.70
Balance Sheet and Cash Flow
Total Cash (mrq)
2.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.23M